| P50 | author | Matteo Ferrando | Q55094094 |
| | Giorgio Walter Canonica | Q56380976 |
| | Francesca Puggioni | Q57985254 |
| | Diego Bagnasco | Q60981423 |
| | Giovanni Passalacqua | Q61949008 |
| | Gilda Varricchi | Q89613143 |
| P2093 | author name string | Marco Caminati | |
| | Alice Bragantini | |
| P2860 | cites work | Anti-IL5 therapy for asthma and beyond | Q26866943 |
| | Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs | Q28067081 |
| | Personalized Medicine in Allergy | Q28073074 |
| | Reslizumab for Poorly Controlled, Eosinophilic Asthma | Q29040017 |
| | Changing roles of eosinophils in health and disease | Q33787311 |
| | Specificity in cytokine signal transduction: lessons learned from the IL-3/IL-5/GM-CSF receptor family. | Q33943220 |
| | Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia | Q34230967 |
| | Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF | Q34270711 |
| | Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. | Q34303895 |
| | Eosinophils: multifaceted biological properties and roles in health and disease | Q34630341 |
| | Treatment of patients with the hypereosinophilic syndrome with mepolizumab | Q34762186 |
| | Characterization of exhaled particles from the human lungs in airway obstruction. | Q35184631 |
| | Pathogenesis of nasal polyposis | Q35576619 |
| | Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models | Q35627697 |
| | Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes | Q36573038 |
| | Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial | Q61959735 |
| | Effects of an antibody to interleukin-5 in a monkey model of asthma | Q71954025 |
| | Involvement of IL-5 in a murine model of allergic pulmonary inflammation: prophylactic and therapeutic effect of an anti-IL-5 antibody | Q72007976 |
| | Relationship between urinary cysteinyl leukotriene E4 levels and clinical response to antileukotriene treatment in patients with asthma | Q80059774 |
| | Inflammatory subtypes in asthma: assessment and identification using induced sputum | Q82306348 |
| | Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome | Q84893066 |
| | Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma | Q36654007 |
| | Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients | Q36765753 |
| | Epithelial eotaxin-2 and eotaxin-3 expression: relation to asthma severity, luminal eosinophilia and age at onset | Q36839587 |
| | Exhaled breath condensate eicosanoid levels associate with asthma and its severity | Q37138368 |
| | T-helper type 2-driven inflammation defines major subphenotypes of asthma. | Q37343774 |
| | Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study | Q37371731 |
| | The consequences of not having eosinophils. | Q37561562 |
| | Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. | Q37694601 |
| | Mepolizumab and exacerbations of refractory eosinophilic asthma | Q37711391 |
| | Innate immunity in the lung regulates the development of asthma | Q38221348 |
| | Biomarker discovery in asthma and COPD by proteomic approaches. | Q38245908 |
| | Emerging molecular phenotypes of asthma | Q38261186 |
| | Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma? | Q38632790 |
| | The path to personalized medicine in asthma. | Q38843261 |
| | A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma | Q39090432 |
| | Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial | Q39408906 |
| | Biomarkers in COPD. | Q39873017 |
| | Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials | Q41452053 |
| | Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients | Q41751510 |
| | Sputum ADAM8 expression is increased in severe asthma and COPD. | Q42260613 |
| | Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma | Q43049820 |
| | Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study | Q43841288 |
| | CCL26/eotaxin-3 is more effective to induce the migration of eosinophils of asthmatics than CCL11/eotaxin-1 and CCL24/eotaxin-2. | Q44795042 |
| | Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts | Q45294119 |
| | Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial | Q45297326 |
| | Mepolizumab for prednisone-dependent asthma with sputum eosinophilia | Q46098864 |
| | Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. | Q46424938 |
| | Hypereosinophilic syndrome and mepolizumab | Q46515296 |
| | Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial | Q47249808 |
| | Mepolizumab treatment in patients with severe eosinophilic asthma | Q48065984 |
| | Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial | Q48509747 |
| | Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. | Q49032278 |
| | Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis | Q49046464 |
| | Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps | Q49069941 |
| | Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. | Q51026334 |
| | Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies? | Q51527018 |
| | Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. | Q51534265 |
| | External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. | Q51682051 |
| | Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. | Q51699006 |
| | Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. | Q51699174 |
| | A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. | Q53176283 |
| | An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. | Q53226482 |
| | Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. | Q53583932 |
| | Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. | Q53850475 |
| P433 | issue | 7 | |
| P921 | main subject | interleukins | Q194908 |
| P304 | page(s) | 559-570 | |
| P577 | publication date | 2017-07-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations | |
| P478 | volume | 40 | |